Development of Analytical Methods for the Determination of N-Bromosuccinimide in Different Active Pharmaceutical Ingredients by High-Performance Ion Chromatography with Suppressed Conductivity Detection

Abstract

Product safety is important for medicines. For drugs on the market, it must be demonstrated that the levels of toxic contaminants are below the permitted limits. These impurities are used as reagents or are generated during synthesis. N-bromosuccinimide is used as a brominating agent in the synthesis of some active pharmaceutical ingredients. The determination of N-bromosuccinimide is difficult due to its high reactivity. In this work, a high-performance ion chromatographic method was developed for the determination of N-bromosuccinimide. The ion chromatographic measurement can be performed in two ways, one involves the assay of the resulting bromide ion and the other is via the assay of the 3-carbamoyl propanoic acid ion produced from the succinimide. Both acid ions were analyzed on an anion exchange column by gradient elution with potassium hydroxide eluent and detection was performed by a suppressed conductivity detector. During the method development, the results showed that the measurement of bromide ion was more selective than the measurement of 3-carbamoyl propanoic acid ion. Two different types of active pharmaceutical ingredients (API), i.e., prasugrel and favipiravir, were chosen to test the developed method and sample preparation. For both APIs, sample preparation was performed in a vial and consists of liquid–liquid extraction with an alkaline reagent. Finally, the anion exchange ion chromatography method was validated at the limit value level, and harmonized with the guidelines. For prasugrel, the quantification limits and the accuracy at the limit level are 7.2 ppm and 96.4%, while for favipiravir these are 7.5 ppm and 114.7%, respectively.

Keywords

• N-bromosuccinimide
• hydrolysis
• liquid–liquid extraction
• ion chromatography
• active pharmaceutical ingredients
• validation